Literature DB >> 34767470

Clinical features and diagnostic tools in idiopathic inflammatory myopathies.

Konstantinos I Tsamis1,2,3, Constantinos Boutsoras1, Evripidis Kaltsonoudis4, Eleftherios Pelechas4, Ilias P Nikas2, Yannis V Simos3, Paraskevi V Voulgari4, Ioannis Sarmas1.   

Abstract

Idiopathic inflammatory myopathies (IIMs) are rare autoimmune disorders affecting primarily muscles, but other organs can be involved. This review describes the clinical features, diagnosis and treatment for IIMs, namely polymyositis (PM), dermatomyositis (DM), sporadic inclusion body myositis (sIBM), immune-mediated necrotizing myopathy (IMNM), and myositis associated with antisynthetase syndrome (ASS). The diagnostic approach has been updated recently based on the discovery of circulating autoantibodies, which has enhanced the management of patients. Currently, validated classification criteria for IIMs allow clinical studies with well-defined sets of patients but diagnostic criteria to guide the care of individual patients in routine clinical practice are still missing. This review analyzes the clinical manifestations and laboratory findings of IIMs, discusses the efficiency of modern and standard methods employed in their workup, and delineates optimal practice for clinical care. Α multidisciplinary diagnostic approach that combines clinical, neurologic and rheumatologic examination, evaluation of electrophysiologic and morphologic muscle characteristics, and assessment of autoantibody immunoassays has been determined to be the preferred approach for effective management of patients with suspected IIMs.

Entities:  

Keywords:  Polymyositis (PM); antisynthetase syndrome (ASS); dermatomyositis (DM); immune-mediated necrotizing myopathy (IMNM); sporadic inclusion body myositis (sIBM)

Mesh:

Substances:

Year:  2021        PMID: 34767470     DOI: 10.1080/10408363.2021.2000584

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  2 in total

1.  A Matrix Prediction Model for the 6-Month Mortality Risk in Patients With Anti-Melanoma Differentiation-Associated Protein-5-Positive Dermatomyositis.

Authors:  Zhi-Ming Ouyang; Jian-Zi Lin; Ao-Juan Tang; Ze-Hong Yang; Li-Juan Yang; Xiu-Ning Wei; Qian-Hua Li; Jin-Jian Liang; Dong-Hui Zheng; Bing-Peng Guo; Gui Zhao; Qian Han; Lie Dai; Ying-Qian Mo
Journal:  Front Med (Lausanne)       Date:  2022-04-01

2.  Hsp90 as a Myokine: Its Association with Systemic Inflammation after Exercise Interventions in Patients with Myositis and Healthy Subjects.

Authors:  Xiao Švec; Hana Štorkánová; Maja Špiritović; Kryštof Slabý; Sabína Oreská; Aneta Pekáčová; Barbora Heřmánková; Kristýna Bubová; Petr Česák; Haya Khouri; Gulalai Amjad; Heřman Mann; Martin Komarc; Karel Pavelka; Ladislav Šenolt; Josef Zámečník; Jiří Vencovský; Michal Tomčík
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.